verzenio Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Verzenio, and what generic alternatives are available?
Verzenio is a drug marketed by Eli Lilly And Co and is included in one NDA. There is one patent protecting this drug.
This drug has fifty-one patent family members in forty-five countries.
The generic ingredient in VERZENIO is abemaciclib. One supplier is listed for this compound. Additional details are available on the abemaciclib profile page.
DrugPatentWatch® Generic Entry Outlook for Verzenio
Verzenio was eligible for patent challenges on September 28, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 15, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for verzenio?
- What are the global sales for verzenio?
- What is Average Wholesale Price for verzenio?
Summary for verzenio
| International Patents: | 51 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 83 |
| Clinical Trials: | 42 |
| Patent Applications: | 580 |
| Drug Prices: | Drug price information for verzenio |
| What excipients (inactive ingredients) are in verzenio? | verzenio excipients list |
| DailyMed Link: | verzenio at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for verzenio
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for verzenio
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Breast Cancer Research Foundation | Phase 2 |
| Bayer | Phase 1/Phase 2 |
| Praful Ravi | Phase 1/Phase 2 |
Pharmacology for verzenio
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Kinase Inhibitors |
US Patents and Regulatory Information for verzenio
verzenio is protected by nine US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of verzenio is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting verzenio
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20%
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Protein kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
FDA Regulatory Exclusivity protecting verzenio
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
INDICATION FOR THE USE OF ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, NODE-POSITIVE, EARLY CANCER (EBC) AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE>20% AS DETERMINED BY AN FDA APPROVED TEST
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-003 | Sep 28, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-002 | Sep 28, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-003 | Sep 28, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-004 | Sep 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-004 | Sep 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-002 | Sep 28, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for verzenio
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly Nederland B.V. | Verzenios | abemaciclib | EMEA/H/C/004302 Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. |
Authorised | no | no | no | 2018-09-26 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for verzenio
When does loss-of-exclusivity occur for verzenio?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 4575
Patent: COMPUESTO DE BENZOIMIDAZOL-PIRIMIDIN-AMINOPIRIDINA, FORMA CRISTALINA III RELACIONADA, FORMULACION FARMACEUTICA QUE LO COMPRENDE Y SU USO PARA PREPARAR UN MEDICAMENTO UTIL PARA TRATAR UN CANCER
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09330365
Patent: Protein kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0924183
Patent: inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 47055
Patent: INHIBITEURS DE PROTEINE KINASES (PROTEIN KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 11001527
Patent: Compuestos derivados de n-(piridin-2-il)-4-(2-metil-1h-benzo[d]imidazol-6-il)-pirimidin-2-amina; forma cristalina iii de [5-(4-etil-piperazin-1-ilmetil)-piridin-2-il]-[5-fluoro-4-(7-fluoro-3-isoptopil-2-metil-3h-benzoimidazol-5-il)-pirimidin-2-il] amina; composicion farmaceutica; y su uso para el tratamiento de cancer.
Estimated Expiration: ⤷ Sign Up
China
Patent: 2264725
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 82125
Patent: INHIBIDORES DE PROTEÍNA QUINASA
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 110343
Patent: INHIBIDORES DE PROTEÍNA CINASA
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0131051
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 14841
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 79528
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 011000204
Patent: INHIBIDORES DE PROTEINA CINASA
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 11011157
Patent: INHIBIDORES DE PROTEÍNA CINASA
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8808
Patent: ИНГИБИТОРЫ ПРОТЕИНКИНАЗЫ, ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ НА ИХ ОСНОВЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ (PROTEIN KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION BASED THEREON AND THERAPEUTICAL USE)
Estimated Expiration: ⤷ Sign Up
Patent: 1170872
Patent: ИНГИБИТОРЫ ПРОТЕИНКИНАЗЫ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 79528
Patent: INHIBITEURS DE PROTÉINE KINASES (PROTEIN KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 0190008
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1100181
Estimated Expiration: ⤷ Sign Up
Honduras
Patent: 11001701
Patent: INHIBIDORES DE PROTEINA CINASA
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 59630
Patent: PROTEIN KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 00509
Estimated Expiration: ⤷ Sign Up
Patent: 900014
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3350
Patent: מעכבי פרוטאין קינאז, תכשירים רוקחיים המכילים אותם ושימושם להכנת תרופות לטיפול בסרטן (Protein kinase inhibitor compounds, pharmaceutical compositions comprising them and their use in the preparation of medicaments for the treatment of cancer)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 17453
Estimated Expiration: ⤷ Sign Up
Patent: 12513396
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 85
Patent: مثبطات بروتين كيناز (PROTEIN KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 379528
Estimated Expiration: ⤷ Sign Up
Patent: 2019004
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 0106
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 0547
Patent: PROTEIN KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 11006757
Patent: INHIBIDORES DE PROTEINA CINASA. (PROTEIN KINASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 903
Patent: مثبطات البروتين كيناز
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 0969
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 3114
Patent: Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 19009
Estimated Expiration: ⤷ Sign Up
Panama
Patent: 52901
Patent: INHIBIDORES DE PROTEINA CINASA
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 120107
Patent: INHIBIDORES DE PROTEINA CINASA
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 79528
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 79528
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 061
Patent: INHIBITORI PROTEIN KINAZE (PROTEIN KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 2331
Patent: PROTEIN KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 79528
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1104505
Patent: PROTEIN KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1297497
Estimated Expiration: ⤷ Sign Up
Patent: 110091551
Patent: PROTEIN KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 35798
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 29635
Estimated Expiration: ⤷ Sign Up
Patent: 1031653
Patent: Protein kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 11000293
Patent: PROTEIN KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 4603
Patent: ІНГІБІТОРИ ПРОТЕЇНКІНАЗ[ИНГИБИТОРЫ ПРОТЕИНКИНАЗ (PROTEIN KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering verzenio around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 1114841 | ⤷ Sign Up | |
| Denmark | 2379528 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2010075074 | ⤷ Sign Up | |
| Guatemala | 201100181 | "INHIBIDORES DE PROTEINA CINASA" | ⤷ Sign Up |
| Brazil | PI0924183 | inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso | ⤷ Sign Up |
| Slovenia | 2379528 | ⤷ Sign Up | |
| European Patent Office | 2379528 | INHIBITEURS DE PROTÉINE KINASES (PROTEIN KINASE INHIBITORS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for verzenio
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379528 | 132019000000037 | Italy | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB(VERZENIOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1307, 20181001 |
| 2379528 | 2019/015 | Ireland | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/18/1307 20180927 |
| 2379528 | 122019000010 | Germany | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB; REGISTRATION NO/DATE: EU/1/18/1307 20180927 |
| 2379528 | C201930017 | Spain | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1307; DATE OF AUTHORISATION: 20180927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1307; DATE OF FIRST AUTHORISATION IN EEA: 20180927 |
| 2379528 | CA 2019 00008 | Denmark | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1307 20181001 |
| 2379528 | 300969 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1307 20181001 |
| 2379528 | LUC00106 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VERZENIOS); AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
